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Introduction. During the natural evolution of prostate cancer in patients treated with prostatectomy many of them develop
biochemical relapse and need radiation treatment.
Objective. To ﬁnd potential predictor factors to response to radiotherapy in prostate cancer patients with biochemical relapse
after prostatectomy.
Methods. We have selected the 59 prostate cancer patients treated with prostatectomy from 2006 to 2008 that were submitted
after biochemical relapse. We have analyzed the following variables to see their impact on the response to the radiotherapy: pN,
Gleason [≤7 (3 + 4) vs. ≥7 (4 + 3)], irradiated volume, dose delivered (<70Gy vs. 70Gy), hormonal treatment (yes/no), and PSA level
before radiotherapy. Follow up: mean 49 months (range 30–69).
Results. Two patients (3.39%) died (one for prostate cancer). 57 patients (96.61%) are still alive, of which 39 (66.10%) remain free of
disease; 13 (22.03%) developed biochemical relapse and 6 (10.20%) distant metastases. PSA pre-radiotherapy was the only variable
analyzed that showed a statistically signiﬁcant incidence p=0.0002 (HR 1254, 95% CI 0.107, 0.345). These results indicate that
for every unit that PSA pre-radiotherapy raises, the risk of developing biochemical relapse is 25% higher. In our series, patients
with PSA> of 1.65ng/ml had a risk of recurrence 3.95 times higher than those with a PSA ≤1.65 (p=0.0049). Gleason, hormonal
treatment and dose delivered: no showed statistically signiﬁcant p values but their survival curves show a clear positive trend
in patients with Gleason ≤7 (3 + 4), who received hormonal treatment and in which dose was ≥70Gy. Volume treated and, pN:
showed no statistical signiﬁcance.
Conclusions. In our series the only variable that has demonstrated statistically signiﬁcance as a predictor factor was PSA pre-
radiotherapy (p=0.0002). Patients with PSA pre-radiotherapy >1.6ng/ml had 3.95 times more risk to developing biochemical
relapse.
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Background. The aim was to obtain the time to nadir of PSA (nPSA) in patients with disease free of recurrence in low risk carcinoma
of prostate cancer, treated with radical external beam radiotherapy (EBRT). And to study the bounce PSA.
Materials and methods. A group of 45 patients, with low risk prostate cancer, (it was considered low risk prostate cancer, those
patients with PSA≤10ng/ml, Gleason=6 or stage T1–T2), who were treated in the years 2007–2009 either using external-beam
RT (78Gy) to prostate volume, without blockage androgen. The treatment was carried out in a lineal accelerator using photons
of 18 MV, with standard technique and fractionation. After baseline prostate-speciﬁc antigen determination (PSApreRT), PSA
was assessed 3 months after the start RTE, and after it was measured every six months. The median follow-up after RT was 27
months with a rate (21–51 months). A bounce was deﬁned by a minimum rise in PSA of 0.4ng/ml over a 6-month period, followed
by a decrease without therapeutic intervention.
Results. The median PSApreRT was 7.35. Median nPSA value was 0.51ng/ml (limits: 0–1.52) and the median time elapsed between
PSApreRT and nPSA has been of 22 months (limits: 9–45). PSA bounce >0.5ng/ml was noted in 18% of patients. After 6 months
the values return close to nPSA values. The median length of time until the ﬁrst PSA bounce was 24 months. None patient had
relapse biochemical by the Phoenix deﬁnition.
Conclusion. In patients with low risk prostate cancer, when EBRT is used as monotherapy, time to nadir is very long. In our cohort
were found benign PSA bounces. Our study reinforces the need for adequate follow-up to ensure accurate estimates of treatment
efﬁcacy and to avoid unnecessary secondary interventions.
http://dx.doi.org/10.1016/j.rpor.2013.03.507
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Introduction. Hypognadism is awell known factor related to the adipose tissue increase, cardiovascular risk and skeletalmyopathy.
Aim. Quantitative CT scans have shown a fat redistribution and a decrease in bone density secondary to hypogonadism. Andro-
genic blockade (AB) induces an hypogonadism status and thus prostate cancer patients are expected to show a fat redistribution
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on CT scans. The aim of our study was to quantify over the time, with serial CT, fat and loan changes related to this induced
status.
Methods. CT scans from 52 prostate cancer patients treated with androgenic blockade were reviewed. CT sets were analyzed
with the MIPAV software (v.4.4.1, U.S. National Institutes of Health) using the abdomen segmentation plugin and the grow region
tool. Fat and loan areas and mean Hounsﬁeld units (HU) were recorded from abdominal total, subcutaneous and visceral fat
tissue, as well as waist and hip circumferences. Patients had a basal CT scan and another study one, two or three years later.
Nonparametric paired statistics were used.
Results. Forty-sixmenunderwent androgenic blockade (AB), and six patients didnot receive anti-androgens.Meanabdominal area
signiﬁcantly increased one year after the start of AB, but could not reach signiﬁcance at second and third year. Lean abdominal
area signiﬁcantly decreased parallelly. There were not differences among the variables analyzed between patients who received
AB and patients who did not received.
Conclusions. Hypogonadism has been related to an adipose redistribution, our results have demonstrated also a fat redistribution,
but the small size sample has prevent to obtain a statistical signiﬁcance.
http://dx.doi.org/10.1016/j.rpor.2013.03.508
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Introduction. Most prostate cancers express androgen receptors. Patients with advanced disease are treated with androgen depri-
vation, androgen receptors blocking or both.
Objective. Between 70 and 80% of patients initially respond to androgen suppressive therapy. Radical radiotherapy is still an option
for the patient with prostate cancer clinically conﬁned to prostate gland treated with androgen deprivation monotherapy and
cataloged as castration refractory, based on delay of progression disease.
Method. Patient 76 years old, with no history of interest came to his doctor for prostatic syndrome with elevated PSA (402.5ng/ml).
Prostate biopsy showed a prostate adenocarcinoma, Gleason 4+4 on all cylinders tested, high-risk by D’Amico (T2c). Staging
workup was negative. The patient was no considered a candidate for radiation therapy for high risk of subclinical disease spread,
due to high PSA levels at baseline. The patient received complete androgen deprivation with Bicalutamide and LHRH analogue
with PSA nadir at 10 months of 1.3ng/ml. After two years of treatment, a biochemical failure is detected without distal clinical
failure. After two hormonal manipulations (antiandrogen withdrawal, estramustine phosphate) and ﬂeeting response of 10
months, the patient was in biochemical progression without distal disease. The hypothetical utility prostate radiation therapy
was raised, a reference dose of 50Gy was received with prostate overprint on to complete a 76Gy standard fractionation dose.
Result. Tolerance to treatment was good. With post-radiotherapy follow up of 18 months, the patient is asymptomatic, continuing
treatment with LHRH analogue and biochemical control (PSA of 1.2ng/ml).
Conclusion. Although we do not have sufﬁcient evidence to give a curative role to the radiotherapy in the treatment of these
patients, it can provide a higher quality of life, with a decrease in the rate of local progression and therefore an increased on the
time until the overall progression of the disease.
http://dx.doi.org/10.1016/j.rpor.2013.03.509
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Introduction. Radiotherapy treatment in patients with prostheses is complex. The presence of high atomic number materials
results in radiation attenuation through the prosthesis, affecting the optimal PTV coverage. Usually a treatment plan tries to
avoid the radiation beams entering through the prosthesis. In cases with bilateral hip prostheses the treatment design is even
more demanding, because of the avoidance of beam entrance through the affected hips can cause unacceptable doses in the
organ at risk (OARs), besides compromising the optimal dose homogeneity in the PTV and its good coverage.
Material and method. 66-year-old patient with bilateral hip prosthesis, diagnosed with biochemical relapse (0.34 PSAng/mL) of an
ADC of prostate Gleason 6, intervened (pT2a positive margin of 2mm) in 2011, was referred to our service for rescue treatment.
A 3DCRT treatment was dismissed by its rectal high toxicity. 5 IMRT treatment plans were designed, varying energies and ﬁelds
arrangement. For plan evaluation, dose-volume histograms (DVH) and the conformity index (CI) were calculated and compared.
Results. Analyzing the DVH of the OARs, all IMRT techniques obtained similar results, with doses below the constraints found
in the literature. IC was above its limit value (=1), which indicates a good coverage of the PTV in the ﬁve techniques, varying in
the range (1.53–1.94). The chosen technique was the IMRT plan with 11 not coplanar ﬁelds and energy of 6MV. Doses to the OAR
rectum were V30: 35%, V40: 32%, V50: 27%, V60: 20%, and V65: 13%. The only immediate side effect was proctitis grade 2 to the
60Gy. After 3-month follow up the patient remains asymptomatic.
